HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) recently announced significant developments regarding its private placement agreement. On January 28, 2025, NRx Pharmaceuticals, Inc. entered into an Amended ...

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in almost three weeks, drawing heavy ...

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

On Friday, NRX Pharmaceuticals Inc (NRXP) stock saw a decline, ending the day at $4.01 which represents a decrease of $-0.25 or -5.87% from the prior close of $4.26. The stock opened at $4.12 and ...

NRx Pharmaceuticals, Inc. appointed Mike Taylor as a Class I member of its Board of Directors. Taylor, aged 50, brings with him 25 years of experience in the global credit business, specializing in ...

HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP) ...

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

The Company has recently announced execution of an agreement for $27 million in funding for HOPE <a target=_blank href= ...